Platelet Rich Plasma (PRP) Clinical Trial
Official title:
Systemic Effects After Local Injection of Platelet-rich Plasma
Verified date | March 2017 |
Source | Chang Gung Memorial Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Objective Platelet-rich plasma (PRP) is widely utilized in the treatment of sports injuries
with favorable outcomes. However, potential systemic effects after localized PRP injection
are unclear at present.
Design: prospective randomized study Methods Twenty-four Taiwanese male athletes with
tendinopathy were randomized into a PRP group (n = 13) or a saline group (n = 11).
Status | Completed |
Enrollment | 24 |
Est. completion date | March 28, 2018 |
Est. primary completion date | November 21, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | N/A and older |
Eligibility |
Inclusion Criteria - Adult male athletes were diagnosed with tendinitis Exclusion Criteria: - Receive local injections and surgery within three months - Systemic disease - Diagnosis of anemia |
Country | Name | City | State |
---|---|---|---|
Taiwan | Chang Gung Medical Hosptial | Kaohsiung |
Lead Sponsor | Collaborator |
---|---|
Chang Gung Memorial Hospital |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Urinary excretion of endogenous AAS metabolites | Doping substances in urine, mainly metabolites of anabolic androgenic steroids (AAS), were quantified, including testosterone (17ß-hydroxyandrost-4-en-3-one), epitestosterone (17a- hydroxy-4-androsten-3-one), androsterone (4-androsten-3,17-dione), etiocholanolone (3a-hydroxy-5ß-androstan-17-one), DHEA (dehydroepiandrosterone), dihydroandrosterone (5a- androstane-3a,17ß-diol), and etiocholane-3a,17ß-diol (5ß -androstane-3a,17ß-diol). Each urine sample (6 mL) was mixed with 50 µL standard solution and 1 mL phosphate buffer, and the mixture was heated for 60 min at 50°C. After cooling at room temperature, liquid-liquid extraction was performed, and phase separation was achieved. The organic extract was evaporated to dryness, and the dried residue was further derivatized with 50 µL of MSTFA solution for 30 min at 60°C. Finally, the sample was subjected to gas chromatographic analysis and mass spectrometric analysis for quantification of doping substances of interest. | 1 week |